The expansion of less invasive, catheter-based endovascular procedures combined with the simplification and miniaturization of inferior vena cava (IVC) filters and their delivery systems has irrevocably altered the procedure of vena cava interruption. What once required a laparotomy for caval "clipping" may now be a 10-minute, percutaneous filter insertion using ultrasound guidance at the bedside. Such dramatic changes make the current, liberalized use of these devices (particularly among the critically ill or injured) understandable. However, any rapidly evolving intervention should be regularly scrutinized, and Dr Streiff's monograph provides a studious and extensively referenced review of the modern practice of IVC filter use.
Dr Streiff's rigorous review of almost 250 reports leads the reader to conclude that we should not use IVC filters as often as we do. Throughout the manuscript, we are reminded that much of the available data regarding IVC filters is scientifically unreliable. Even the most valid prospective comparison of IVC filters to anticoagulant therapy [1] excluded many complex cases and reported primary endpoints of thrombotic complications that were not controlled for the use of antithrombotic therapy (which may be acceptable since we do not really even have Class A scientific evidence that heparin is effective treatment for deep vein thrombosis [DVT]). Realistically, validation (by Dr Streiff's scientific standards) for IVC filter use in many clinical situations will never be forthcoming, just as we will never have a scientifically rigorous study proving heparin prevents pulmonary embolism (PE) in patients with acute DVT. Some of our business just has to be intuitive.
Pulmonary embolism remains one of the most frequent causes of death among adult hospitalized patients, and PE may be the single most preventable cause of death among high-risk patient groups. It is most devastating when PE is fatal in a person who would be expected to otherwise recover from his or her illness, surgery, or traumatic injury, and these deaths continue despite the widespread use of mechanical and pharmacologic prophylaxis, even low molecular weight heparins. We cannot prevent all deaths, and we cannot prevent all PEs, but what we can do is try to prevent fatal PE. If the prevention of fatal pulmonary embolism is our singular endpoint, then we can accomplish this goal in one of the following ways:
• Prevent DVT with effective prophylaxis • Diagnose and treat DVTs that have not been prevented, before they embolize • Prevent migration of established DVT into the pulmonary circulation by mechanical venous interruption (IVC filter)
The latter strategy is the least elegant but may be the most predictable in the highest-risk cases. IVC filters do nothing to prevent DVT. All current IVC filters are fenestrated, and smaller thrombi can embolize through the filter and even be "symptomatic" but not fatal. Is caval thrombosis following IVC filter placement a "bad" thrombotic complication or is it a "good" trapping of the massive embolism that would have been fatal without the filter? To be fair to these poor inert devices, the prevention of fatal PE should be the only relevant clinical endpoint by which the efficacy of IVC filters is judged, since this alone has been the only goal of venous interruption throughout medical history. The crucial role of IVC filters in the prevention of fatal PE becomes intuitively evident when we examine how the other "standard" strategies for prevention of fatal PE fail.
Prevent DVT. Consensus studies [2] have described "very high risk" patient groups as ones with a > 8% incidence of proximal DVT that is associated with a 1% to 5% risk of fatal PE. Geerts [3] reported an 18% incidence of proximal DVT in trauma patients who received no DVT prophylaxis. Even the most successful DVT prophylaxis may result in a 50% reduction of DVT in treatment groups compared with controls. Thus, effective DVT prophylaxis in multitrauma patients theoretically reduces the incidence of proximal DVT to 9%-but this is still in the very high risk category for fatal PE. Here, "scientifically valid" data prove that we have reduced DVT, but the patient remains at high risk for fatal PE. Thus, logically (if not scientifically) to reduce the risk of fatal PE, our therapeutic strategy in some of these cases must extend beyond prevention alone. This has been the clinical experience with multitrauma patients that has led some to recommend "prophylactic" IVC filter placement.
Diagnose and Treat DVTs Before They Embolize.
Prospective surveillance using venous ultrasound scanning diagnosed proximal DVT in more than 5% of neurosurgical patients receiving standard DVT prophylaxis [4] . (Consensus rating [2] = "high risk" for fatal PE.) More than 80% of these proximal DVTs were asymptomatic at the time of diagnosis; they were not prevented by prophylaxis, nor would they have been diagnosed by standard practice, but they clearly remained as a risk for PE. All proximal DVTs were treated by placement of an IVC filter and, in this group of more than 2600 patients, the incidence of fatal PE was 0.07%. Thus, a high-risk group with proximal DVT was converted into a low-risk (or almost no-risk) group for fatal PE by the selective use of IVC filters. The most reliable aspect of unreliable data is that they support one position no more or less than another. I possess no scientific evidence that was overlooked by Dr Streiff, and I am only citing 6 references, not 200, so here is what I believe to be intuitive:
IVC filters prevent early acute, fatal PE. In the "best" study [1] cited by Dr Streiff, none of the patients receiving IVC filters died of acute PE, while 80% of early deaths in the non-IVC filter group was due to pulmonary embolism. It has been estimated that 30,000 to 40,000 IVC filters are placed each year in the United States, and if they were not accomplishing the primary goal of prevention of fatal PE, we would certainly know after 30 years of experience (see "heparin for DVT" above). Filters do not prevent death-they prevent death due to pulmonary embolism.
There are some patient groups in whom medical treatments do not work well enough to prevent fatal PE. These cases (like the multitrauma cases noted above) may intuitively require the addition of IVC interruption to impact the outcome of fatal pulmonary embolism. Prospective ultrasound studies of acute DVT [5] observed clot propagation in up to 30% of cases, even when anticoagulant therapy was in the "therapeutic" range. If I have a large, free-floating IVC thrombus, give me an IVC filter. When I find any practicing physician who would want heparin alone for himself or herself or his or her relatives in that situation, then I'll become more conservative.
Patients who receive IVC filters will have a higher incidence of thrombotic complications. In the distant past, we tried to intentionally thrombose aortic aneurysms by filling them full of wire. Thus, it seemed to me miraculous that any IVC would remain patent after placement of a Bird's Nest filter, but our prospective evaluation [6] indicated that these filters produced no higher rate of IVC thrombosis than any other. Nevertheless, no rational physician would expect that one could place a variety of goofy-looking metal devices in the venous system of patients without an increased risk of thrombotic complications, which was observed in the study of Decousus et al. [1] However, the long-term clinical impact of these complications has remained more theoretic than real over 3 decades of experience with IVC filters. There have been hundreds of thousands of these devices placed in the last 30 years, and if there were an unacceptably high rate of morbid late complications, it would be painfully evident by now. I also suspect that, for the patients, this theoretic risk of postthrombotic complications may be slightly overshadowed by the prevention of their fatal pulmonary embolism.
Patients who receive IVC filters will have a lower risk of thromboembolic complications if they can be safely maintained on antithrombotic therapy. We believe antithrombotic therapy prevents DVT. We believe antithrombotic therapy prevents thromboembolism in patients with acute DVT. The best evidence [1] indicates that patients having IVC filters have a higher incidence of thrombotic complications. Is a prospective randomized comparison required to convince us that antithrombotic therapy would reduce the risks of thromboembolic complications in patients with IVC filters? Most patients receive IVC filters because they cannot (safely, at the time) receive antithrombotic therapy. After filter placement, if they can, or when they can receive antithrombotic therapy, they should.
Removable/retrievable IVC filters are not the panacea we all await. When these devices are not anchored well to the IVC, they migrate; when they are attached well enough, removal may include some of the wall of the IVC (which is probably not good). Removable filters have to be attached to the outside world by wires or catheters, so, like all central venous lines, they get infected. The majority of patients considered for IVC filter placement have a high-risk period that is not confined to a small number of days; the high-risk period may even extend beyond the period of hospitalization, and most "retrievable" filters are simply never retrieved. For other than a small and very select group of patients with thromboembolic complications, retrievable filters may be more trouble than they will be worth.
The late, nonthrombotic complications of IVC filter placement remain anecdotal. I have had a decades-long, deep, abiding concern that the liberalization of the indications for IVC filter placement, particularly in younger patients with an extended life expectancy, would lead to an ever-increasing incidence of late, horrific complications. But it simply hasn't happened. Currently, we preferentially stuff metallic foreign bodies into our patients' iliac arteries, their coronary arteries, their renal arteries, and even (God forbid) their carotid arteries, often without the benefit of randomized prospective trials. We do this because it is less invasive (just like IVC filters are less invasive than vena cava clipping), and because we believe intuitively that it is the best thing for the patients at that time. In the majority of cases, we have been right.
Randomized prospective studies were not performed to prove the efficacy of Listerian antisepsis, to test penicillin, appendectomy, or, for that matter, heparin. Patients present with endless combinations and permutations of injuries, complications, and comorbidities. We have the AIS, ISS, and APACHE that have not gained universal application, so we start out not being able to decide which patients are which. Add to this an ever-expanding variety of devices (maybe we need a drug-eluting IVC filter), and this array of uncontrollable variables makes "good science" almost an oxymoron. Dr. Streiff's monograph should remind us, as scientists, to be reflective, but it must not paralyze us as clinicians. IVC filters save lives. When your best clinical judgment suggests that the risk of acute, fatal PE in your patient would be significantly reduced by placement of an IVC filter, you are probably right.
